IRIS-Coroflex NEO Cohort

Launched by SEUNG-JUNG PARK · Dec 11, 2023

Keywords

ClinConnect Summary

The IRIS-Coroflex NEO Cohort trial is a study aimed at understanding how well the Coroflex ISAR NEO stents work compared to other similar stents that release medication to help keep arteries open. This research is important for patients with coronary artery disease, which is when the blood vessels supplying the heart become narrow or blocked. The trial is not yet recruiting participants, but once it begins, it will include individuals aged 19 and older who will be treated with the Coroflex ISAR NEO stents.

To take part in this study, patients must provide written consent and agree to follow the study’s schedule. However, some individuals may not be eligible, including those who have other types of stents or serious health issues that could affect the study's outcomes. Participants can expect regular check-ups to monitor their health and the performance of the stent. This trial will help doctors understand the best options for treating coronary artery disease in everyday clinical settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients ≥ 19 years old
• • 2. Patients receiving Coroflex ISAR NEO stents.
• • 3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
• Exclusion Criteria:
• • 1. Patients with a mixture of other DESs
• • 2. Terminal illness with life expectancy \<1 year.
• • 3. Patients with cardiogenic shock